Publicacións (66) Publicacións de Miriam Saiz Rodriguez

2024

  1. Cómo estimar la composición corporal en la enfermedad de Huntington. Estudio transversal y observacional con bioimpedancia de múltiples frecuencias

    Revista de neurologia, Vol. 78, Núm. 1, pp. 17-25

  2. Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain

    Clinical and Translational Science, Vol. 17, Núm. 1

  3. The association between lifestyle factors and mortality in Huntington's disease

    Neurologia

2023

  1. 'Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation' by Ali et al. - reassess the evidence, shall we?

    Pharmacogenetics and genomics, Vol. 33, Núm. 4, pp. 88-89

  2. Association Between Insulin-Like Growth Factor-1 and Social Cognition in Huntington's Disease

    Movement Disorders Clinical Practice, Vol. 10, Núm. 2, pp. 279-284

  3. Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives

    Journal of Personalized Medicine, Vol. 13, Núm. 4

  4. Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers

    Journal of Personalized Medicine, Vol. 13, Núm. 3

  5. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus

    Pharmacogenomics, Vol. 24, Núm. 12, pp. 651-663

  6. Occupational performance in Huntington’s disease: A cross-sectional study

    British Journal of Occupational Therapy, Vol. 86, Núm. 6, pp. 432-440

  7. Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives

    Journal of Personalized Medicine, Vol. 13, Núm. 3

  8. “Pharmacogenetics of siponimod: A systematic review” by Díaz-Villamarín et al. – Information is power

    Biomedicine and Pharmacotherapy

2022

  1. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 483-494

  2. F46 Phase angle as indicator of sarcopenia in Huntington´s disease

    F: Clinical studies: case reports, observational studies and trials

  3. Polymorphisms in the oxytocin receptor and their association with apathy and impaired social cognition in Huntington’s disease

    Neurological Sciences, Vol. 43, Núm. 10, pp. 6079-6085

  4. Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives

    Pharmaceutics, Vol. 14, Núm. 3

  5. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

    Cancers, Vol. 14, Núm. 7

2021

  1. Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin

    Frontiers in Pharmacology, Vol. 12

  2. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling

    Clinical Pharmacokinetics, Vol. 60, Núm. 2, pp. 261-270

  3. HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B∗ 57:01 genotyping to predict abacavir hypersensitivity reaction in Spain

    Pharmacogenetics and Genomics, Vol. 31, Núm. 3, pp. 53-59

  4. High-Fat Breakfast Increases Bioavailability of Albendazole Compared to Low-Fat Breakfast: Single-Dose Study in Healthy Subjects

    Frontiers in Pharmacology, Vol. 12